


A PERFECT
MATCH
WITH NGS


THE IDYLLA™ PLATFORM



ULTRA-RAPID IDYLLA™ TESTING COMPLEMENTS NGS

Despite the clear advantages of comprehensive molecular profiling by next-generation sequencing (NGS), the associated testing complexity often translates into long turnaround times (TAT). Rapid mutation assessment through alternate methods remains critical for key genomic alterations. The Idylla™ system facilitates ultra-rapid assessment of key molecular markers which can be seamlessly integrated into virtually any laboratory workflow and used concurrently with NGS.

CURRENT MOLECULAR TESTING OPTIONS IN ONCOLOGY




THE BEST OF BOTH WORLDS: ULTRA-RAPID RESULTS OF MOST COMMON MUTATIONS COMBINED WITH COMPREHENSIVE MOLECULAR PROFILING



OPTIMIZED TESTING EFFICIENCY IN LARGE LABORATORY SETTINGS - REAL WORLD EXAMPLES



LUNG CANCER TESTING IN A LARGE ACADEMIC CENTER, NEW YORK, NY⁶




IDYLLA™ IMPACT

- Turnaround time for rapid EGFR testing reduced from 9 days to 1-3 days
- Simple workflow allows implementation of ultra-rapid testing solution without requiring additional resources
- Flexible platform is able to handle the variety of different sample types coming into the lab
- Use of minimal material allows further testing by NGS assays



CRC TESTING IN A LARGE LABORATORY, DANVILLE, PA⁷



IDYLLA™ IMPACT

- Turnaround time for RAS/BRAF testing reduced from 4-7 days to 1-2 days
- 1 FTE freed up due to full-automated testing nature
- Internal test menu expanded

IDYLLA™ AND NGS - A PERFECT MATCH



REDUCED TIME TO RESULT FOR KEY BIOMARKERS

- On demand testing with short assay turnaround times
- Minimal sample manipulation



MINIMAL ADDITIONAL RESOURCES NEEDED

- Fully automated walk-away system
- Under three min hands-on time per sample



REDUCED COST

- Cost-effective even for smaller sample volumes, no batching needed
- Only a subset of samples has to be reflexed to NGS



MINIMAL SAMPLE REQUIREMENTS & VERSATILE SAMPLE TYPES

- Various types possible, including FFPE, fresh tissue, plasma, DNA^{8,9}
- Reliable results even for small & challenging samples

REFERENCES

- (1) Dagogo-Jack I et al. (2018), JCO Precision Oncology; Epub 2018 Jul 24.
- (2) Mackinnon A et al. (2019) Journal of Molecular Diagnostics; 21(5): 862-872.
- (3) Ghigna M et al. (2018) Journal of Thoracic Disease; 10(7): 4653-4658.
- (4) Al-Turkmani et al. (2018) Modern Pathology; 32 Abstract #581.
- (5) Brohawn DG et al. (2019) Journal of Diagnostic Techniques and Biomedical Analysis; 7:2.
- (6) Nafa et al (2019) Journal of Molecular Diagnostics; 21(6), Abstract #ST028.
- (7) Ding Y 2019, presented at the Biocartis Corporate Workshop, AMP Annual Meeting 2019, www.biocartis.com/en-US/publications.
- (8) Arcila M et al. (2018) Journal of Molecular Diagnostics; 20(6) Abstract #ST027.
- (9) Al-Turkmani, R et al. (2018) Clinical Chemistry; 64(5): 865-866.

Contact details

Biocartis US Inc.

2 Pierce Place Suite 1510

Itasca, IL 60143

1-844-4-IDYLLA (1-844-443-9552)

www.biocartis.com/US

customerserviceUS@biocartis.com

Follow us on   

For Research Use Only. Not for use in diagnostic procedures.

Copyright information

The Idylla™ platform is available as an IVD in Europe and many other countries outside the US and is cleared in the US under K163628. Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis. © February 2023, Biocartis US Inc. All rights reserved.

